Heather Bresch, Robert Cindrich join Mylan’s board
PITTSBURGH — Mylan’s board of directors now includes the drug maker’s president.
Mylan said its board of directors now includes Mylan president Heather Bresch and Robert Cindrich, who currently serves as senior adviser to the office of the president at the University of Pittsburgh Medical Center, a global health enterprise.
With the additions of Bresch and Cindrich, Mylan’s board now has 11 members.
Cold sore treatment Xerese enters market
HUDDINGE, Sweden — Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.
The Swedish drug maker launched Xerese (acyclovir and hydrocortisone), a topical combination product designed to treat recurrent herpes simplex labialis.
Medivir said the U.S. market for cold sore products is $230 million, and it expected the drug to be successful, given Meda’s presence in the U.S. market.
Forest gets nod for COPD drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for chronic obstructive pulmonary disease made by Forest Labs, the agency said Tuesday.
The FDA announced the approval of Daliresp (roflumilast), a daily pill designed to decrease the frequency of flare-ups or worsening of symptoms from severe COPD. The agency said the drug did not have a brand name at the time of approval, though Forest already had chosen one at the time of this writing. The drug is for people with severe COPD to treat the symptoms of cough and excess mucus linked with bronchitis, but not primary emphysema. COPD comprises both diseases.
“COPD is a serious disease that gets worse over time,” FDA Office of Drug Evaluation II director Curtis Rosebraugh said. “New treatment options that reduce frequency of flare-ups or exacerbations are important in helping patients with COPD associated with chronic bronchitis and a history of exacerbations in managing this debilitating disease.”